Comparison 6. Adalimumab weekly versus placebo.

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 Change in DLQI score (imputation) (negative values indicate improvement in DLQI)	1		Mean Difference (IV, Fixed, 95% CI)	Totals not selected
2 Change in DLQI score (LOCF) (negative values indicate improvement in DLQI)	1		Mean Difference (IV, Fixed, 95% CI)	Totals not selected
3 Frequency of serious adverse effects	1		Risk Ratio (M‐H, Fixed, 95% CI)	Totals not selected
4 Frequency of treatment discontinuation	1		Risk Ratio (M‐H, Fixed, 95% CI)	Totals not selected
5 Proportion of participants with infectious adverse effects	1		Risk Ratio (M‐H, Fixed, 95% CI)	Totals not selected
6 Proportion of participants with improvement in pain	1		Risk Ratio (M‐H, Fixed, 95% CI)	Totals not selected
7 Change in modified Sartorius scale score (imputation) (higher scores associated with more severe disease)	1		Mean Difference (IV, Fixed, 95% CI)	Totals not selected
8 Change in modified Sartorius scale score (LOCF) (higher scores associated with more severe disease)	1		Mean Difference (IV, Fixed, 95% CI)	Totals not selected
9 Physician Global Assessment (at least a grade 2 improvement from baseline)	1		Risk Ratio (M‐H, Fixed, 95% CI)	Totals not selected
10 Total Work Productivity Impairment (TWPI) score (imputation) (lower number indicates less impairment)	1		Mean Difference (IV, Fixed, 95% CI)	Totals not selected
11 Total Work Productivity Impairment (TWPI) score (LOCF) (lower number indicates less impairment)	1		Mean Difference (IV, Fixed, 95% CI)	Totals not selected